Trametinib (Pipeline)

Trametinib (Pipeline)
Product Description

A targeted-oncology pipeline opportunity associated with metastatic melanoma.

Dosage form: Film-coated tablet Strengths: 0.5 mg and 2 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Metastatic melanoma Product class: Protein kinase inhibitor Dossier status: Available Estimated CPP timing: Q3 2027 The two-strength film-coated tablet presentation may complement future targeted-oncology portfolios.

Medis ehf.

  • Country/Region:
    Iceland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Specifications
  • Details
    A targeted-oncology pipeline opportunity associated with metastatic melanoma.

    Dosage form: Film-coated tablet Strengths: 0.5 mg and 2 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Metastatic melanoma Product class: Protein kinase inhibitor Dossier status: Available Estimated CPP timing: Q3 2027 The two-strength film-coated tablet presentation may complement future targeted-oncology portfolios.

Medis ehf.

  • Country/Region:
    Iceland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
Licensee
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist

More Products from Medis ehf. (26)

  • Losartan (Reformulation)

    Product Losartan (Reformulation)

    A four-strength angiotensin II receptor blocker opportunity undergoing reformulation.

    Dosage form: Film-coated tablet Strengths: 12.5 mg, 25 mg, 50 mg and 100 mg Therapeutic area: Cardiovascular Key indication: Hypertension Product class: Angiotensin II re...
  • Melatonin (Commercial)

    Product Melatonin (Commercial)

    A prolonged-release oral product associated with circadian-rhythm sleep disorders.

    Dosage form: Prolonged-release tablet Strength: 2 mg Therapeutic area: Nervous system Key indication: Circadian-rhythm sleep disorders Product class: Hypnotic and sedative a...
  • Out-licensing

    Product Out-licensing

    Medis is an established provider of dossiers and products in all areas of the world with launches and marketing authorizations in over 140 countries to date.
  • Palbociclib (Pipeline)

    Product Palbociclib (Pipeline)

    An oral pipeline opportunity associated with the treatment of breast cancer.

    Dosage form: Film-coated tablet Strengths: 75 mg, 100 mg and 125 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Breast cancer Product class:...
  • Pregabalin (Reformulation)

    Product Pregabalin (Reformulation)

    A broad-strength central nervous system reformulation opportunity.

    Dosage form: Hard capsule Strengths: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg Therapeutic area: Nervous system Key indication: Neuropathic pain Product class: Analgesic Exp...
  • Ruxolitinib (Pipeline)

    Product Ruxolitinib (Pipeline)

    A multi-strength hematology pipeline opportunity associated with myelofibrosis.

    Dosage form: Tablet Strengths: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Myelofibrosis Product clas...
  • Alprazolam (Reformulation)

    Product Alprazolam (Reformulation)

    A four-strength anxiolytic tablet portfolio undergoing reformulation.

    Dosage form: Tablet Strengths: 0.25 mg, 0.5 mg, 1 mg and 2 mg Therapeutic area: Nervous system Key indication: Anxiety Product class: Anxiolytic Dossier status: Available Estimated CPP timi...
  • Amlodipine / Indapamide / Perindopril Arginine (Commercial)

    Product Amlodipine / Indapamide / Perindopril Arginine (Commercial)

    A three-component fixed-dose combination opportunity for partners seeking to expand their cardiovascular portfolio.

    Dosage form: Film-coated tablet Strengths: 5 mg/1.25 mg/5 mg, 5 mg/2.5 mg/10 mg, 10 mg/1.25 mg/5 mg and 10 mg/2.5 mg/10 mg Therapeutic area: Cardiovas...
  • Apremilast (Commercial)

    Product Apremilast (Commercial)

    An oral product opportunity associated with immune-mediated conditions, including plaque psoriasis and psoriatic arthritis.

    Dosage form: Film-coated tablet Strengths: 10 mg, 20 mg and 30 mg Therapeutic area: Antineoplastic and immunomodulating agents Key ind...
  • Atenolol (Reformulation)

    Product Atenolol (Reformulation)

    A three-strength beta-blocker opportunity undergoing reformulation.

    Dosage form: Tablet Strengths: 25 mg, 50 mg and 100 mg Therapeutic area: Cardiovascular Key indication: Hypertension Product class: Beta-blocking agent Dossier status: Available The three-...
  • Azacitidine (Pipeline)

    Product Azacitidine (Pipeline)

    An oral pipeline opportunity associated with maintenance therapy for adults with acute myeloid leukaemia.

    Dosage form: Film-coated tablet Strengths: 200 mg and 300 mg Therapeutic area: Antineoplastic and immunomodulating agents Key indication: Maintenance therapy for adults with acute myeloid le...
  • Bisoprolol Fumarate (Reformulation)

    Product Bisoprolol Fumarate (Reformulation)

    A broad cardiovascular portfolio opportunity with six strengths.

    Dosage form: Film-coated tablet Strengths: 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg Therapeutic area: Cardiovascular Key indication: Hypertension Product class: Beta-blocking agent E...

Medis ehf. resources (2)